Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Identifieur interne : 003254 ( PubMed/Corpus ); précédent : 003253; suivant : 003255Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Auteurs : Thibault Renoir ; Andrew Argyropoulos ; Caroline Chevarin ; Laurence Lanfumey ; Anthony J. HannanSource :
- Pharmacology, biochemistry, and behavior [ 1873-5177 ] ; 2014.
English descriptors
- KwdEn :
- 3,4-Dihydroxyphenylacetic Acid (antagonists & inhibitors), 3,4-Dihydroxyphenylacetic Acid (metabolism), Animals, Disease Models, Animal, Dopamine (metabolism), Dopamine Uptake Inhibitors (pharmacology), Dopamine Uptake Inhibitors (therapeutic use), Female, Huntington Disease (drug therapy), Huntington Disease (genetics), Huntington Disease (metabolism), Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Receptors, Dopamine D1 (antagonists & inhibitors), Receptors, Dopamine D1 (metabolism), Sex Characteristics.
- MESH :
- chemical , antagonists & inhibitors : 3,4-Dihydroxyphenylacetic Acid, Receptors, Dopamine D1.
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Dopamine, Receptors, Dopamine D1.
- chemical , pharmacology : Dopamine Uptake Inhibitors.
- chemical , therapeutic use : Dopamine Uptake Inhibitors.
- drug therapy : Huntington Disease.
- genetics : Huntington Disease.
- metabolism : Huntington Disease.
- Animals, Disease Models, Animal, Female, Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Sex Characteristics.
Abstract
Using the R6/1 transgenic mouse model of Huntington's disease (HD), we have recently shown that acute administration with the dopamine-norepinephrine reuptake inhibitor bupropion was able to rescue depressive-like behaviours in female HD mice at 12weeks of age.
DOI: 10.1016/j.pbb.2014.10.004
PubMed: 25316307
Links to Exploration step
pubmed:25316307Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.</title><author><name sortKey="Renoir, Thibault" sort="Renoir, Thibault" uniqKey="Renoir T" first="Thibault" last="Renoir">Thibault Renoir</name><affiliation><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia. Electronic address: thibault.renoir@unimelb.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Argyropoulos, Andrew" sort="Argyropoulos, Andrew" uniqKey="Argyropoulos A" first="Andrew" last="Argyropoulos">Andrew Argyropoulos</name><affiliation><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Chevarin, Caroline" sort="Chevarin, Caroline" uniqKey="Chevarin C" first="Caroline" last="Chevarin">Caroline Chevarin</name><affiliation><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lanfumey, Laurence" sort="Lanfumey, Laurence" uniqKey="Lanfumey L" first="Laurence" last="Lanfumey">Laurence Lanfumey</name><affiliation><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hannan, Anthony J" sort="Hannan, Anthony J" uniqKey="Hannan A" first="Anthony J" last="Hannan">Anthony J. Hannan</name><affiliation><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25316307</idno><idno type="pmid">25316307</idno><idno type="doi">10.1016/j.pbb.2014.10.004</idno><idno type="wicri:Area/PubMed/Corpus">003254</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003254</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.</title><author><name sortKey="Renoir, Thibault" sort="Renoir, Thibault" uniqKey="Renoir T" first="Thibault" last="Renoir">Thibault Renoir</name><affiliation><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia. Electronic address: thibault.renoir@unimelb.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Argyropoulos, Andrew" sort="Argyropoulos, Andrew" uniqKey="Argyropoulos A" first="Andrew" last="Argyropoulos">Andrew Argyropoulos</name><affiliation><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Chevarin, Caroline" sort="Chevarin, Caroline" uniqKey="Chevarin C" first="Caroline" last="Chevarin">Caroline Chevarin</name><affiliation><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lanfumey, Laurence" sort="Lanfumey, Laurence" uniqKey="Lanfumey L" first="Laurence" last="Lanfumey">Laurence Lanfumey</name><affiliation><nlm:affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hannan, Anthony J" sort="Hannan, Anthony J" uniqKey="Hannan A" first="Anthony J" last="Hannan">Anthony J. Hannan</name><affiliation><nlm:affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Pharmacology, biochemistry, and behavior</title><idno type="eISSN">1873-5177</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid (antagonists & inhibitors)</term><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Uptake Inhibitors (pharmacology)</term><term>Dopamine Uptake Inhibitors (therapeutic use)</term><term>Female</term><term>Huntington Disease (drug therapy)</term><term>Huntington Disease (genetics)</term><term>Huntington Disease (metabolism)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Inbred CBA</term><term>Mice, Transgenic</term><term>Receptors, Dopamine D1 (antagonists & inhibitors)</term><term>Receptors, Dopamine D1 (metabolism)</term><term>Sex Characteristics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term><term>Dopamine</term><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Inbred CBA</term><term>Mice, Transgenic</term><term>Sex Characteristics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Using the R6/1 transgenic mouse model of Huntington's disease (HD), we have recently shown that acute administration with the dopamine-norepinephrine reuptake inhibitor bupropion was able to rescue depressive-like behaviours in female HD mice at 12weeks of age.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25316307</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2015</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5177</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pharmacology, biochemistry, and behavior</Title><ISOAbbreviation>Pharmacol. Biochem. Behav.</ISOAbbreviation></Journal><ArticleTitle>Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.</ArticleTitle><Pagination><MedlinePgn>15-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pbb.2014.10.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-3057(14)00278-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Using the R6/1 transgenic mouse model of Huntington's disease (HD), we have recently shown that acute administration with the dopamine-norepinephrine reuptake inhibitor bupropion was able to rescue depressive-like behaviours in female HD mice at 12weeks of age.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this present study, we aimed to further investigate the dopamine system as well as specifically measure dopamine transporter (DAT) and D1 receptor function in female versus male R6/1 HD mice at a very early stage of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We assessed the effects of acute administration of bupropion and the dopamine D1 receptor agonist SKF-8129 on spontaneous locomotor activity in 8-week-old HD and wild-type (WT) mice. We also measured dopamine levels in striatum via high performance liquid chromatography (HPLC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that female (but not male) HD mice were hyposensitive to bupropion when compared to WT littermates. However, both female and male HD mice were less sensitive to SKF-81297 locomotor effects. We also found that striatal dopamine levels and dopamine turnover were reduced in HD animals, regardless of sex.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our present findings suggest that whereas only female HD mice exhibit an impaired response to bupropion, dopamine D1 receptor function is altered in both female and male HD animals. These data are the first in vivo evidence of impaired dopamine D1 receptor-dependent function in pre-motor symptomatic HD mice suggesting that this is a candidate target for early therapeutic interventions.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Renoir</LastName><ForeName>Thibault</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia. Electronic address: thibault.renoir@unimelb.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argyropoulos</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevarin</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanfumey</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Inserm UMR S894, F-75013 Paris, France; UPMC, University of Paris 06, UMR S894, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannan</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia; Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Biochem Behav</MedlineTA><NlmUniqueID>0367050</NlmUniqueID><ISSNLinking>0091-3057</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>102-32-9</RegistryNumber><NameOfSubstance UI="D015102">3,4-Dihydroxyphenylacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015102" MajorTopicYN="N">3,4-Dihydroxyphenylacetic Acid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018765" MajorTopicYN="N">Dopamine Uptake Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bupropion</Keyword><Keyword MajorTopicYN="N">Dopamine</Keyword><Keyword MajorTopicYN="N">Huntington's disease</Keyword><Keyword MajorTopicYN="N">Locomotor activity</Keyword><Keyword MajorTopicYN="N">Sex differences</Keyword><Keyword MajorTopicYN="N">Tandem repeat disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25316307</ArticleId><ArticleId IdType="pii">S0091-3057(14)00278-0</ArticleId><ArticleId IdType="doi">10.1016/j.pbb.2014.10.004</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003254 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003254 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25316307
|texte= Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25316307" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |